Last updated: June 4, 2026
JADENU SPRINKLE (deferasirox) is supplied in the U.S. by Novartis Pharmaceuticals Corporation and is supported by a vertically managed supply chain centered on Novartis manufacturing and packaging sites for the drug product, with raw material supply for deferasirox and excipients typically sourced through Novartis’ controlled vendor network.
Who are the manufacturers and suppliers for JADENU SPRINKLE (deferasirox) in the U.S.?
Novartis Pharmaceuticals Corporation is the U.S. marketing authorization holder for JADENU SPRINKLE. The company’s supply chain for the commercial product is built around Novartis’ own drug-product manufacturing and secondary packaging, with active pharmaceutical ingredient (API) production and excipient sourcing handled through qualified supplier networks.
What supply chain roles exist for JADENU SPRINKLE
JADENU SPRINKLE supply is typically structured into four procurement buckets:
- API (deferasirox): produced by qualified API manufacturers and supplied to Novartis for formulation
- Drug product: granulation, blending, and controlled-size particle manufacturing to meet sprinkle dosage performance
- Packaging: unit-dose or container-closure system packaging (bottles, cartons, labels)
- Distribution: controlled logistics for cold-chain is not typically required, but temperature and humidity controls apply
Which company is listed as the drug’s U.S. supplier
- Marketing holder / distributor in the U.S.: Novartis Pharmaceuticals Corporation
(Commercial supply for the branded product runs through the brand owner’s distribution channel.)
Which CDMO or contract manufacturers are involved in JADENU SPRINKLE production?
Public-facing supplier identification for exact CDMO involvement is limited because the branded product supply network often uses internal Novartis manufacturing and contracted, confidential qualification for specific steps such as granulation, coating, and packaging line operations. For branded oral solids like JADENU SPRINKLE, the most material, audit-ready supplier entities are those listed in official FDA product records and labeling supply-chain sections.
Where is JADENU SPRINKLE manufactured (site-level supplier details)?
Site-level manufacturing details for JADENU SPRINKLE are embedded in regulatory submissions and labeling/CMC documentation. For actionable supplier mapping, the controlling sources are:
- FDA review documents for the approved NDA supplement covering “sprinkle” presentations
- The listed manufacturing and packaging facilities associated with the approved NDA product listing
At a business-use level, the manufacturer and packaging-site entities that appear in official FDA records are the supplier contracts’ anchor points for audits, change control, and batch traceability.
What ingredients and input suppliers matter for JADENU SPRINKLE?
The procurement of JADENU SPRINKLE inputs is driven by:
- Deferasirox API (primary critical input)
- Excipients required for sprinkle stability and dispersibility
- Film or matrix-forming components (if applicable to the granule design)
- Container closure system components (liners, caps, induction seals, desiccant if specified)
- Packaging line materials (labels, cartons, lot/exp expiry printing consumables)
Why supplier concentration risk is higher for the API
Deferasirox is the controlling critical material. Any disruption in qualified API supply can force formulation delays, batch rejections, or sourcing changes that require regulatory comparability and stability data.
How can suppliers affect JADENU SPRINKLE availability and pricing?
Supply disruption risk for JADENU SPRINKLE is tied to:
- API lot continuity: changing API supplier can require comparability studies and stability bridging
- Granule performance: dosing uniformity, sprinkle dispersion, and particle-size distribution are sensitive to process and equipment
- Packaging constraints: bottle/cap configuration and label compliance can restrict substitution during shortages
What is the supplier relationship between Novartis and raw material vendors for deferasirox?
Novartis typically uses a qualified supplier model for both API and excipients:
- Vendor qualification includes analytical method capability, impurity profile alignment, and cGMP compliance
- OOS/OOT handling and change control are contractually enforced
- Requalification events occur after material or process changes, reflecting FDA expectations for comparability
How should procurement teams structure vendor qualification for JADENU SPRINKLE-related sourcing?
For procurement, the practical qualification checklist aligns to:
- Vendor cGMP status and inspection history
- API impurity and polymorph controls
- Excipients with documented functional purpose (dispersion and stability)
- Packaging component regulatory status (food-contact-grade polymers where applicable, functional barrier performance)
- Traceability: batch mapping from API COA through drug product lot release
Key Takeaways
- Novartis Pharmaceuticals Corporation is the U.S. marketing/distribution anchor for JADENU SPRINKLE (deferasirox).
- The supply network for the branded oral solid is centered on Novartis-controlled manufacturing and packaging, supported by qualified API and excipient suppliers.
- Supplier concentration risk is driven primarily by deferasirox API continuity and by granule performance-critical process steps.
FAQs
- Who supplies the U.S. distribution of JADENU SPRINKLE (deferasirox)?
- What raw materials are critical to JADENU SPRINKLE manufacturing besides deferasirox API?
- What supplier changes can trigger regulatory comparability work for JADENU SPRINKLE?
- How do packaging suppliers impact JADENU SPRINKLE shortage and compliance during rollouts?
- What manufacturing steps in oral sprinkle granules are most sensitive to supplier variation?
References
- FDA. Drugs@FDA. “JADENU SPRINKLE (deferasirox)”. U.S. Food and Drug Administration. (Accessed via Drugs@FDA product listing and labeling records).
